WO2003101467A1 - Compositions pharmaceutiques comprenant de l'abacavir et de la lamivudine - Google Patents

Compositions pharmaceutiques comprenant de l'abacavir et de la lamivudine Download PDF

Info

Publication number
WO2003101467A1
WO2003101467A1 PCT/US2003/017347 US0317347W WO03101467A1 WO 2003101467 A1 WO2003101467 A1 WO 2003101467A1 US 0317347 W US0317347 W US 0317347W WO 03101467 A1 WO03101467 A1 WO 03101467A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
amino
pharmaceutical composition
cis
oxathiolan
Prior art date
Application number
PCT/US2003/017347
Other languages
English (en)
Inventor
Robin Currie
Gary Wayne Goodson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to US10/516,577 priority Critical patent/US20050171127A1/en
Priority to JP2004508822A priority patent/JP2005532341A/ja
Priority to AU2003231955A priority patent/AU2003231955A1/en
Priority to EP03756359A priority patent/EP1513540A1/fr
Publication of WO2003101467A1 publication Critical patent/WO2003101467A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the present Invention relates to pharmaceutical compositions combining the agents (IS, c/5)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-l -methanol and (2R,cis)-4-amino-l-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(l ⁇ )-pyrimidin-2-one into a single form, useful in the treatment of diseases in mammals, including humans.
  • the succinate salt of (IS, cw)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2- cyclopentene-1 -methanol is described in WO96/06844.
  • the hemisulfate salt of (IS, cw)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-l-methanol is described in WO98/52949.
  • (2R,cis)-4-amino-l-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(lH)-pyrimidin-2-one are described in WO92/21676.
  • Combinations of (2R,cis)-4-amino-l -(2-hydroxymethyl- 1,3 - oxathiolan-5-yl)-(lH)-pyrimidin-2-one with other reverse transcriptase inhibitors are described in WO92/20344.
  • the present invention addresses the issue of non-compliance by formulating multiple active ingredients, (IS, cts)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2- cyclopentene- 1 -methanol and (2R,cis)-4-amino- 1 -(2-hydroxymethyl- 1 ,3 -oxathiolan-5 - yl)-(l ⁇ )-pyrimidin-2-one, into a single tablet.
  • active ingredients (IS, cts)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2- cyclopentene- 1 -methanol and (2R,cis)-4-amino- 1 -(2-hydroxymethyl- 1 ,3 -oxathiolan-5 - yl)-(l ⁇ )-pyrimidin-2-one
  • compositions comprising the active ingredients (IS, cw)-4-[2-amino-6-
  • a further feature of the present invention is to provide a method for using these pharmaceutical compositions.
  • the present invention provides pharmaceutical compositions comprising the active ingredients (IS, c/s)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-l- methanol and (2R,cis)-4-amino- 1 -(2-hydroxymethyl- 1 ,3 -oxathiolan-5-yl)-( 1 ⁇ )- pyrimidin-2-one, or pharmaceutically acceptable derivatives thereof, in the form of a tablet with high drug loading, while maintaining favorable tablet properties and suitable tablet size.
  • a further feature of the present invention is to provide a method for using these pharmaceutical compositions.
  • the present invention features a pharmaceutical composition, comprising:
  • the present invention also features pharmaceutical compositions comprising a safe and therapeutically effective amount of (IS, c/s)-4-[2-amino-6-(cyclopropylamino)-9H- puriu-9-yl]-2-cyclopentene-l -methanol (herein referred to as "abacavir”) or a pharmaceutically acceptable derivative thereof, a safe and therapeutically effective amount of (2R,cis)-4-amino-l-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(l ⁇ )-pyrimidin-
  • compositions of the present invention comprise abacavir and lamivudine as described above wherein the composition exhibits acceptable tablet hardness, for example of greater than 20 kilopounds at 25 kilonewtons of force for a 1375 mg tablet.
  • safe and therapeutically effective amount means a sufficient amount of a drug, compound, composition, product or pharmaceutical agent to abate or reverse or treat a malady in a human or other mammal without severely harming the tissues of the mammal to which the drug or pharmaceutical agent is administered.
  • pharmaceutically acceptable derivative means any pharmaceutically acceptable salt, solvate, ester, or salt of such ester, or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) the intended active ingredient or any active metabolite or residue thereof.
  • phrases "pharmaceutically acceptable derivative of abacavir” as used herein, means any pharmaceutically acceptable salt, solvate, ester, or salt of such ester, of abacavir, or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) abacavir or any antivirally active metabolite or residue thereof.
  • a preferred pharmaceutically acceptable derivative of abacavir is abacavir hemisulfate salt.
  • pharmaceutically acceptable derivative of lamivudine means any pharmaceutically acceptable salt, solvate, ester, or salt of such ester, of lamivudine, or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) lamivudine or any antivirally active metabolite or residue thereof.
  • highly compressible carrier means binder or filler that provides good tableting properties such as tablet hardness, low friability, and flow at quantities significantly lower than conventional fillers or binders such as Avicel ® PH 101, Avicel ® PH012, lactose, and other similar binders or fillers.
  • drug loading means the ratio of drug to total weight of tablet.
  • compositions of the present invention contain highly compressible carriers, for example, diluents, binders or fillers, for example, highly compressible microcrystalline cellulose.
  • highly compressible microcrystalline cellulose are low bulk density and high compressibility, superior compatibility and low friability.
  • the use of highly compressible microcrystalline cellulose enables compaction at lower forces and results in the capability to manufacture harder tablets.
  • disintegration times of compositions made with highly compressible microcrystalline cellulose are faster compared to compositions made with conventional microcrystalline cellulose, for example, Avicel ® PHI 01 and Avicel ® PHI 02, at equivalent tablet hardness.
  • the carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions of the present invention employ a safe and therapeutically effective amounts of abacavir or a pharmaceutically acceptable derivative thereof, and lamivudine or a pharmaceutically acceptable derivative thereof, along with a safe and effective amount of a pharmaceutically acceptable highly compressible carrier.
  • Highly compressible carriers may be diluents, binders, or fillers. Examples include, but are not limited to, highly compressible microcrystalline cellulose, for example, Ceolus ® , ProSolvTM, and Avicel PHI 05 microcrystalline cellulose.
  • the present invention further features a pharmaceutical composition consisting essentially of abacavir, or a pharmaceutically acceptable derivative thereof, lamivudine, and Ceolus ® microcrystalline cellulose
  • compositions of the present invention feature unit dosage forms, for example, tablets containing abacavir and lamivudine, wherein the tablet has a volume of less than 1.5 mL, advantageously less than 1.2 mL, or in the range of 1.0 - 1.3 mL, preferably about 1.1 mL.
  • Tablets of the present invention containing abacavir and lamivudine exhibit properties that are advantageous for administration as a pharmaceutical composition.
  • tablets of the present invention may have a thickness of less than or equal to 8.6 mm, may exhibit low friability ( ⁇ 0.3%), for example, a friability of less than or equal to 0.1 %, may exhibit a hardness of greater than 18 kilopounds for a 1375 mg tablet, and/or may exhibit a disintegration of less than or equal to 20 minutes, advantageously less than or equal to 12 minutes.
  • the present invention features pharmaceutical compositions as described above which are fiowable, compressible, have low friability, good disintegration times, good tablet hardness, and acceptable dissolution.
  • compositions comprising abacavir or a pharmaceutically acceptable derivative thereof, lamivudine or a pharmaceutically acceptable derivative thereof, and Ceolus ® microcrystalline cellulose.
  • Such compositions may have a volume of about 1.1 mL and/or exhibit a hardness of greater than 18 kilopounds and/or exhibit a disintegration of less than or equal to 20 minutes, advantageously less than or equal to 12 minutes.
  • the present invention features a pharmaceutical composition
  • a pharmaceutical composition comprising abacavir, or a pharmaceutically acceptable derivative thereof and lamivudine, or a pharmaceutically acceptable derivative thereof, in an amount from about 20%) to 80% of total compression weight or from about 30% to about 70% of total composition weight.
  • the pharmaceutical composition may advantageously be in the form of a tablet, said tablet having 20% - 80% drug loading or 30% to 60% drug loading, advantageously 40% to
  • lamivudine is provided substantially free of the corresponding (+)- enantiomer.
  • substantially free means that there is less than about 10% w/w of the (+)-enantiomer present compared with the amount of lamivudine.
  • Another feature of the present invention is to simplify treatment regimens for HIV and other viruses with the goal of enhancing patient compliance by providing a simplified dosage form containing pharmaceutically acceptable amounts of abacavir and lamivudine or pharmaceutically acceptable derivatives thereof.
  • the present invention also features a method for treating, reversing, reducing or inhibiting retroviral infections in particular HIV infections, in a mammal, in particular a human, which method comprises administering to said mammal a safe and effective amount of a composition according to the invention.
  • the present invention provides the combined use of abacavir, or a pharmaceutically acceptable derivative thereof, lamivudine, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable highly compressible carrier in the manufacture of a medicament for the treatment of a retroviral infection, in particular an HIV infection.
  • treatment extends to both the prophylaxis and the treatment of an established malady, infection or its symptoms.
  • compositions of the present invention may optionally employ a safe and effective amount of a diluent, a safe and effective amount of a disintegrant, and a safe and effective amount of a lubricant or any other safe and effective amounts of excipients commonly used in the art.
  • compositions of the present invention may include from 0 to about 2% magnesium stearate; from about 0.05 to about 5% glidant; from 0 to about 5% sodium starch glycollate; and from about 20 to about 50% microcrystalline cellulose.
  • the pharmaceutical compositions of the present invention may optionally contain silicon dioxide (SiO 2 ), also referred to as colloidal silica, fumed silicon dioxide, fumed silica, light anhydrous silicic acid, silicic anhydride, AEROSILTM or CAB-O-SILTM; asbestos free talc, sodium aluminosilicate, calcium silicate, powdered cellulose, microcrystalline cellulose, corn starch, sodium benzoate, calcium carbonate, magnesium carbonate, metallic stearates, calcium stearate, magnesium stearate, zinc stearate, stearowet C, starch, starch 1500, magnesium lauryl sulfate, magnesium oxide, colloidal silicon dioxide in combination with microcrystalline cellulose or ProSolvTM.
  • Abacavir may be prepared by the method described in European Patent Specification
  • the succinate salt of 1592U89 may be prepared by the method described in WO96/06844, which is incorporated herein by reference hereto.
  • the hemisulfate salt of 1592U89 may be prepared by the method described in WO98/52949, which is incorporated herein by reference hereto.
  • Preferred salts of abacavir include the succinate salt and the hemisulfate salt.
  • compositions suitable for oral administration may conveniently be presented as discrete units such as tablets, caplets, capsules, or any other form suitable for oral administration and compatible with the compositions of the present invention, each containing a predetermined amount of the active ingredients.
  • a particularly suitable composition may be prepared from direct compression or granulation processes.
  • Such compositions may contain safe and effective amounts of conventional excipients such as binding agents, fillers, lubricants, or disintegrants.
  • the tablets may also be coated according to any method known to persons skilled in the art that would not interfere with the tablets' release properties, or the other physical or chemical characteristics of the present Invention. Tablet coating is further described and delineated by Remington, The Science & Practice of Pharmacy 19th ed.
  • compositions may also be modified by any method known to persons skilled in the art to achieve sustained release of active ingredients.
  • the compositions may also include a safe and effective amount of other active ingredients, such as antimicrobial agents or preservatives.
  • compositions of the present invention are suitable for administration to humans or other mammals particularly via an oral route of administration.
  • oral routes of administration such as pharmacists and nurses are not foreclosed.
  • the amount of active ingredients required for use in treatment will vary according to a variety of factors, including the nature of the condition being treated and the age and condition of the patient, and will ultimately be at the discretion of the attending physician, veterinarian or health care practitioner.
  • a suitable dose of abacavir for administration to a human for treatment of an HIV injection may be in the range of 0.1 to 120 mg per kilogram body weight of the recipient per day, preferably in the range of 3 to 90 mg per kilogram body weight per day and most preferably in the range 5 to 60 mg per kilog am body weight per day.
  • the current recommended oral dose of lamivudine for adults and adolescents is 150 mg twice daily administered in combination with other antiretro viral agents.
  • the current recommended oral dose of lamivudine is 2mg/kg twice daily administered in combination with other antiretroviral agents.
  • the recommended oral dose of lamivudine in paediatric patients 3 months to 12 years of age is 4mg/kg twice daily, up to a maximum of 150 mg twice daily administered in combination with other antiretroviral agents.
  • compositions of the present invention enable patients greater freedom from multiple dosage medication regimens and ease the needed diligence required in remembering complex daily dosing times and schedules.
  • the desired daily doses may be presented in a single dose or as divided doses, administered at appropriate intervals, for example as two, three, four or more sub-doses per day.
  • the compositions of the present invention are particularly suitable for administration as a single dose once daily.
  • the compositions of the present invention may be administered once daily.
  • compositions of the present invention conveniently allow administration of two separate compounds in unit dosage form containing, for example, from about 15 to about 1200 mg of abacavir, particularly from about 100 to about 750 mg of abacavir, and most particularly about 700 mg of abacavir, from about 15 to about 1000 mg of lamivudine, particularly from about 100 to about 500 mg of lamivudine and most particularly 300 mg of lamivudine per unit dosage form.
  • the composition of the present invention may be used in combination with other pharmaceutical formulations as a component of a multiple drug treatment regimen.
  • compositions of the present invention may also be packaged as articles of manufacture comprising a safe and therapeutically effective amount of abacavir, or a pharmaceutically acceptable derivative thereof; and a safe and therapeutically effective amount of lamivudine, or a pharmaceutically acceptable derivative thereof and a safe and effective amount of a pharmaceutically acceptable highly compressible carrier.
  • Tablets, caplets, or other solid dosage forms suitable for oral administration may be packaged and contained in various packaging materials particularly glass and plastic bottles and also including unit dose blister packaging.
  • the packaging material may also have labelling and information related to the pharmaceutical composition printed thereon.
  • an article of manufacture may contain a brochure, report, notice, pamphlet, or leaflet containing product information. This form of pharmaceutical information is referred to in the pharmaceutical industry as a "package insert.”
  • a package insert may be attached to or included with a pharmaceutical article of manufacture.
  • the package insert and any article of manufacture labelling provides information relating to the pharmaceutical composition.
  • the information and labelling provides various forms of information utilised by health-care professionals and patients, describing the composition, its dosage and various other parameters required by regulatory agencies such as the United States Food and Drug Agencies.
  • compositions of the present invention can be formulated using methods and techniques suitable for the compositions physical and chemical characteristics and that are commonly employed by persons skilled in the art in preparing oral dosage forms utilising direct compression or granulation processes.
  • compositions of the present Invention in their method aspect are administered to a human or other mammal in a safe and effective amount as described herein.
  • safe and effective amounts will vary according to the type and size of mammal being treated and the desired results of the treatment.
  • the quantities of the present example of manufacturing procedure are based on a typical batch size of 300 kg and may be adjusted depending on batch size.
  • Ceolus® Microcrystalline Cellulose, NF 67.3
  • Magnesium Stearate 2.0 The components are then sieved using a Russel-SIV equipped with a 14 mesh (1.4mm opening) or an equivalent sieve and mesh, and deposited into a stainless-steel blending container.
  • abacavir, lamivudine, Ceolus®, and sodium starch glycolate, NF are blended for 12 minutes using a suitable blender, such as a Matcon-Buls bin-type blender, a V-b lender or equivalent.
  • a suitable blender such as a Matcon-Buls bin-type blender, a V-b lender or equivalent.
  • the magnesium stearate is then added to the mixture an ⁇ blending is continued for approximately 2 minutes.
  • the lubricated blend is then compressed using a suitable rotary tablet press, typically a Fette 2090 or equivalent.
  • a suitable rotary tablet press typically a Fette 2090 or equivalent.
  • In-process controls for tablet weight and hardness are applied at appropriate intervals throughout the compression run and adjustments to the tablet press are made as necessary.
  • Tablets were weighed on an analytical balance. A digital caliper was used to measure the thickness of the tablets. Tablet hardness was measured on a suitable hardness tester by placing the tablets lengthwise between the crushing jaws. Powder flow was determined by placing a powder sample into a FlodexTM. The sample was then allowed to sit undisturbed for fifteen seconds prior to being discharged through a stainless steel orifice. The orifices were changed as needed until the smallest size was determined that allowed the powder to flow freely. Friability and disintegration was measured according to the current U.S. Pharmacopeia (USP 25-NF 20).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant (1S, cis)-4-[2-amino-6-(cyclopropylamino)-9H-purine-9-yl]-2-cyclopentène-1-méthanol et (2R,cis)-4-amino-1-(2-hydroxyméthyl-1,3-oxathiolane-5-yl)-(1H)-pyrimidine-2-one, en quantité suffisante pour assurer une efficacité antivirale, un procédé de préparation de ladite composition et un procédé d'inhibition du virus de l'immunodéficience humaine (VIH) consistant à administrer une telle composition à un patient infecté par le VIH.
PCT/US2003/017347 2002-06-04 2003-06-03 Compositions pharmaceutiques comprenant de l'abacavir et de la lamivudine WO2003101467A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/516,577 US20050171127A1 (en) 2002-06-04 2003-06-03 Pharmaceutical compositions comprising abacavir and lamivudine
JP2004508822A JP2005532341A (ja) 2002-06-04 2003-06-03 アバカビルとラミブジンを含有する医薬組成物
AU2003231955A AU2003231955A1 (en) 2002-06-04 2003-06-03 Pharmaceutical compositions comprising abacavir and lamivudine
EP03756359A EP1513540A1 (fr) 2002-06-04 2003-06-03 Compositions pharmaceutiques comprenant de l'abacavir et de la lamivudine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38571702P 2002-06-04 2002-06-04
US60/385,717 2002-06-04

Publications (1)

Publication Number Publication Date
WO2003101467A1 true WO2003101467A1 (fr) 2003-12-11

Family

ID=29712206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017347 WO2003101467A1 (fr) 2002-06-04 2003-06-03 Compositions pharmaceutiques comprenant de l'abacavir et de la lamivudine

Country Status (7)

Country Link
US (1) US20050171127A1 (fr)
EP (1) EP1513540A1 (fr)
JP (1) JP2005532341A (fr)
AR (1) AR040242A1 (fr)
AU (1) AU2003231955A1 (fr)
TW (1) TW200403061A (fr)
WO (1) WO2003101467A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013047A2 (fr) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Compositions pharmaceutiques anti-retrovirales dispersibles dans l'eau
WO2011156594A2 (fr) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Immunisation thérapeutique chez des patients infectés par le vih recevant un traitement antirétroviral stable
RU2705570C1 (ru) * 2018-06-27 2019-11-08 федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации Способ прогнозирования прогрессирующего фиброза печени и выбора комбинации препаратов для антиретровирусной терапии при коинфекции ВИЧ/ВГС

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8568777B2 (en) * 2007-03-30 2013-10-29 Monosol Rx, Llc Packaged film dosage unit containing a complexate
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
EP2958563A2 (fr) * 2013-02-20 2015-12-30 AbbVie Inc. Formes posologiques sous forme de comprimés

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030025A1 (fr) * 1995-03-30 1996-10-03 The Wellcome Foundation Limited Combinaisons synergiques de zidovudine, 1592u89 et 3tc ou ftc
WO1999055372A1 (fr) * 1998-04-29 1999-11-04 Glaxo Group Limited Compositions pharmaceutiques homogenes comportant de l'abacavir, de la lamiduvine et de la zidovudine
WO2000016779A1 (fr) * 1998-09-18 2000-03-30 Glaxo Group Limited Combinaisons antivirales contenant de la lamivudine et de l'abacavir

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030025A1 (fr) * 1995-03-30 1996-10-03 The Wellcome Foundation Limited Combinaisons synergiques de zidovudine, 1592u89 et 3tc ou ftc
WO1999055372A1 (fr) * 1998-04-29 1999-11-04 Glaxo Group Limited Compositions pharmaceutiques homogenes comportant de l'abacavir, de la lamiduvine et de la zidovudine
WO2000016779A1 (fr) * 1998-09-18 2000-03-30 Glaxo Group Limited Combinaisons antivirales contenant de la lamivudine et de l'abacavir

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUBERG M ET AL: "Studies on direct compression of tablets. XII. The consolidation and bonding properties of some pharmaceutical compounds and their mixtures with Avicel 105", INTERNATIONAL JOURNAL OF PHARMACEUTICAL TECHNOLOGY AND PRODUCT MANUFACTURE 1985 UNITED KINGDOM, vol. 6, no. 2, 1985, pages 17 - 25, XP009015326 *
LAHDENPAA E ET AL: "DIRECT COMPRESSION WITH SILICIFIED AND NON-SILICIFIED MICROCRYSTALLINE CELLULOSE: STUDY OF SOME PROPERTIES OF POWDERS AND TABLETS", STP PHARMA SCIENCES, PARIS, FR, vol. 11, no. 2, March 2001 (2001-03-01), pages 129 - 135, XP009006009, ISSN: 1157-1489 *
OBAE K ET AL: "Morphological effect of microcrystalline cellulose particles on tablet tensile strength.", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 182, no. 2, 25 May 1999 (1999-05-25), pages 155 - 164, XP001154010, ISSN: 0378-5173 *
VLADYKA R S ET AL: "Evaluation of sphere-forming excipients in high drug loaded theophylline spheres", PROCEEDINGS OF THE CONTROLLED RELEASE SOCIETY 1998 UNITED STATES, no. 25, 1998, pages 948 - 949, XP009015365, ISSN: 1022-0178 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013047A2 (fr) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Compositions pharmaceutiques anti-retrovirales dispersibles dans l'eau
WO2007013047A3 (fr) * 2005-07-29 2007-05-31 Ranbaxy Lab Ltd Compositions pharmaceutiques anti-retrovirales dispersibles dans l'eau
WO2011156594A2 (fr) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Immunisation thérapeutique chez des patients infectés par le vih recevant un traitement antirétroviral stable
RU2705570C1 (ru) * 2018-06-27 2019-11-08 федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации Способ прогнозирования прогрессирующего фиброза печени и выбора комбинации препаратов для антиретровирусной терапии при коинфекции ВИЧ/ВГС

Also Published As

Publication number Publication date
AU2003231955A1 (en) 2003-12-19
US20050171127A1 (en) 2005-08-04
JP2005532341A (ja) 2005-10-27
AR040242A1 (es) 2005-03-23
TW200403061A (en) 2004-03-01
EP1513540A1 (fr) 2005-03-16

Similar Documents

Publication Publication Date Title
US6113920A (en) Pharmaceutical compositions
CA2330391A1 (fr) Compositions pharmaceutiques homogenes comportant de l'abacavir, de la lamiduvine et de la zidovudine
EP0941100B1 (fr) Compositions pharmaceutiques contenant de la lamivudine et de la zidovudine
KR20200070246A (ko) 이중층 제약 정제 제제
US20050171127A1 (en) Pharmaceutical compositions comprising abacavir and lamivudine
EP1567133B1 (fr) Preparations pharmaceutiques antivirales
US20050113394A1 (en) Pharmaceutical compositions
MXPA99004025A (en) Pharmaceutical compositions containing lamivudine and zidovudine
WO2022132676A1 (fr) Forme posologique en mini-comprimé d'un inhibiteur de terminase virale et ses utilisations
MXPA00010498A (en) Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
US20090317466A1 (en) Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10516577

Country of ref document: US

Ref document number: 2004508822

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003756359

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003756359

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003756359

Country of ref document: EP